Author: Ravi Shankar

BOCA RATON, FL, Nov. 10, 2026 (GLOBE NEWSWIRE) — DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced it will host its October 2026 & 3Q 2026 Earnings Recap on Thursday, November 12, 2026, at 11:00 a.m. EST via X Spaces. The event will provide shareholders, analysts, and the broader community with a review of the Company’s accomplishments during October 2026. The discussion will also cover the Company’s third quarter 2026 earnings report, which is expected to be released that morning.

Participants can join the live event through the link below.

https://x.com/i/spaces/1rJqmAQylyNvKk?s=20. 

About DeFi Development Corp.
DeFi Development Corp. (Nasdaq: DFDV) has adopted a treasury policy under which the principal holding in its treasury reserve is allocated to SOL. Through this strategy, the Company provides investors with direct economic exposure to SOL, while also actively participating in the growth of the Solana ecosystem. In addition to holding and staking SOL, DeFi Development Corp. operates its own validator infrastructure, generating staking rewards and fees from delegated stake. The Company is also engaged across decentralized finance (DeFi) opportunities and continues to explore innovative ways to support and benefit from Solana’s expanding application layer.

The Company is also an AI-powered online platform that connects the commercial real estate industry by providing value-add services and software subscriptions to multifamily and commercial property professionals, as the Company connects the increasingly complex ecosystem that stakeholders have to manage. The Company’s data and software offerings are generally offered on a subscription basis as software as a service.

Investor Contact:
ir@defidevcorp.com

Media Contact:
press@defidevcorp.com

• Fiscal 2026 net sales from continuing operations of $151.9 million; Gross margin of 32.0%; Net income from continuing operations per diluted share of $0.16

• Sales order backlog increased 75% to $43.3 million as of the end of fiscal 2026, compared to $24.7 million as of the end of the prior fiscal year 

• Began shipments against the previously announced $22 million data center order, marking a significant milestone in the expansion of our data center business

• Expects full year fiscal 2027 revenue of $195 million to $205 million, representing just over 30% growth from fiscal year 2026 revenue at the midpoint of guidance

MINNEAPOLIS, Nov. 10, 2026 (GLOBE NEWSWIRE) — Clearfield, Inc. (NASDAQ: CLFD), a leader in fiber connectivity solutions for telecom, data center, and network infrastructure environments, reported results for the fiscal fourth quarter and full year 2026. Additional commentary is provided in a letter to shareholders available in the Investor Relations section of the Company’s website.

Fiscal Q4 2026 Financial Summary
(in millions, except per share data and percentages)		Q4 2026				vs. Q4 2025				Change ($)				Change (%)
Net Sales from Continuing Operations		$	39.3			$	41.1			$	(1.7	)		-4	%
Gross Profit ($) from Continuing Operations		$	12.1			$	14.2			$	(2.2	)		-15	%
Gross Profit (%) from Continuing Operations			30.7	%			34.6	%			-4.0	%		-11	%
(Loss) Income from Operations from Continuing Operations		$	(1.0	)		$	1.0			$	(2.0	)		-210	%
Income Tax Expense from Continuing Operations		$	0.5			$	0.8			$	(0.3	)		-40	%
Net (Loss) Income from Continuing Operations		$	(0.1	)		$	1.8			$	(1.9	)		-104	%
Net Income (Loss) per Diluted Share from Continuing Operations		$	0.00			$	0.13			$	(0.13	)		-100	%
Net Income (Loss) from Discontinued Operations, net of tax		$	0.00			$	(0.5	)		$	0.5			100	%
Income (Loss) from Impairment of Discontinued Operations, net of tax		$	0.00			$	(10.4	)		$	10.4			100	%
Net Income (Loss) per Diluted Share from Discontinued Operations		$	0.00			$	(0.78	)		$	0.78			100	%
Consolidated Net Income (Loss) Per Diluted Share		$	0.00			$	(0.65	)		$	0.65			100	%

Fiscal Q4 YTD 2026 Financial Summary
(in millions, except per share data and percentages)		YTD Q4 2026				vs. YTD Q4 2025				Change ($)				Change (%)
Net Sales from Continuing Operations		$	151.9			$	150.1			$	1.8			1	%
Gross Profit ($) from Continuing Operations		$	48.6			$	50.5			$	(2.0	)		-4	%
Gross Profit (%) from Continuing Operations			32.0	%			33.7	%			-1.7	%		-5	%
(Loss) Income from Operations from Continuing Operations		$	(2.4	)		$	2.1			$	(4.5	)		-212	%
Income Tax Expense from Continuing Operations		$	1.2			$	2.4			$	(1.1	)		-48	%
Net Income from Continuing Operations		$	2.1			$	6.3			$	(4.2	)		-66	%
Net Income per Diluted Share from Continuing Operations		$	0.16			$	0.45			$	(0.29	)		-64	%
Net Loss from Discontinued Operations, net of tax		$	(0.3	)		$	(3.9	)		$	3.6			91	%
Income (Loss) from Impairment of Discontinued Operations, net of tax		$	0.00			$	(10.4	)		$	10.4			100	%
Net Loss per Diluted Share from Discontinued Operations		$	(0.02	)		$	(1.03	)		$	1.01			98	%
Consolidated Net Income (Loss) per Diluted Share		$	0.14			$	(0.58	)		$	0.72			124	%

Management Commentary

“Fiscal 2026 represented a pivotal transition year for Clearfield.  We continued serving our established broadband customers while expanding our fiber management expertise to the rapidly growing AI infrastructure market.  This last quarter, we have seen a positive sign in the Broadband market as Clearfield announced shipments to one of the first BEAD funded deployments here in Minnesota as well as the beginning of shipments to our first significant data center customer site.  We believe this demonstrates the work that has been accomplished to date and the significant growth we see in front of us,” said Cheri Beranek, President and Chief Executive Officer. “Since co-founding Clearfield in 2008, it has been a privilege to help build the Company alongside our dedicated team. As previously announced, I plan to retire effective March 31, 2027, or earlier upon the appointment of my successor. I will continue as President and CEO Emeritus to support the transition. I am proud of what we have accomplished and confident in Clearfield’s next phase of growth under new leadership.”

“Over the past three fiscal years, we have strengthened our financial position through disciplined balance sheet management, including strong cash generation and thoughtful capital allocation. During that period, we generated approximately $41 million in cumulative free cash flow and returned $65 million to shareholders through share repurchases. With $157 million in cash and investments and no debt, we have the flexibility to invest in our business and expand our addressable markets,” said Dan Herzog, Chief Financial Officer. “We are excited about the growth opportunities ahead in fiscal 2027, with revenue expected to be in the range of $195 million to $205 million, supported by an anticipated gradual recovery in broadband demand and the expected ramp-up of our data center business.”

Financial Results for the Three Months Ended September 30, 2026
Net sales from continuing operations for the fourth quarter of fiscal 2026 were $39.3 million, compared to $41.1 million in the prior year quarter.

As of September 30, 2026, order backlog (defined as purchase orders received but not yet fulfilled) was $43.3 million, an increase of $22.3 million, or 106%, compared to $21.0 million as of June 30, 2026, and an increase of $18.6 million, or 75%, from September 30, 2025.

Gross profit margin from continuing operations in the fourth quarter was 30.7%, compared with 34.6% in the prior year quarter and 31.8% in the third quarter.

Operating expenses from continuing operations for the fourth quarter of fiscal 2026 decreased to $13.1 million, or 33.3% of net sales, from $13.3 million, or 32.3% of net sales, in the same year-ago quarter.

Net loss from continuing operations for the fourth quarter of fiscal 2026 totaled $73,000, or $0.00 per diluted share, compared to net income of $1.8 million, or $0.13 per diluted share, in the same year-ago quarter. The Company repurchased approximately 60,000 shares for $1.8 million during the 3-month period ended September 30, 2026. There is approximately $13.2 million remaining for future repurchases as of September 30, 2026. 

Financial Results for the Year Ended September 30, 2026
Net sales from continuing operations were $151.9 million, compared to $150.1 million in fiscal year 2025. Performance for the quarter and full year reflected growth in the Large Regional segment, partly offset by softness in the MSO market.

Gross margin from continuing operations decreased from 33.7% in fiscal year 2025 to 32.0%. Gross profit margin for the fourth quarter and full year of fiscal 2026 was affected by higher product costs absorbed compared to prior periods, particularly in the latter part of the fiscal year.

Operating expenses from continuing operations for fiscal 2026 were $50.9 million, up 5% from $48.4 million in fiscal year 2025. As a percentage of net sales, operating expenses increased to 33.5%, from 32.3% in fiscal 2025.

Net income from continuing operations for fiscal 2026 was $2.1 million, down from $6.3 million in fiscal 2025. Earnings per diluted share from continuing operations decreased to $0.16 in fiscal 2026 from $0.45 per diluted share in fiscal 2025.

Outlook
For fiscal 2027, we expect net sales to be in the range of $195 million to $205 million, and net income per share to a range of $0.25 to $0.46. For the first quarter of fiscal 2027, we expect net sales in the range of $48 million to $52 million, operating expenses as a percentage of net sales to remain consistent with the fourth quarter of fiscal 2026, and net income (loss) per share in the range of $(0.06) to $0.03. 

The net income (loss) per share ranges are based on the number of shares outstanding at the end of the fourth quarter of fiscal 2026 and do not reflect the impact of any potential additional share repurchases completed in fiscal 2027. Our guidance also reflects our current expectations regarding the current data center environment and potential supply chain constraints of optical fiber, cable and connectors mentioned in our previous letters to shareholders, as well as our current understanding of the impact of the evolving tariff situation, both which could contribute to uncertainty in our business and in the macroeconomic environment.

Conference Call
Management will hold a conference call today, November 10, 2026, at 5:00 p.m. Eastern Time (4:00 p.m. Central Time) to discuss these results and provide an update on business conditions.

Clearfield’s President and Chief Executive Officer, Cheri Beranek, and Chief Financial Officer, Dan Herzog, will host the presentation, followed by a question-and-answer period.

U.S. dial-in: 1-844-501-2063
International dial-in: 1-412-365-5136
Conference ID: 10212806

The live webcast of the call can be accessed at the Clearfield Investor Relations website along with the company’s earnings press release and presentation.

A replay of the call will be available after 8:00 p.m. Eastern Time on the same day through November 24, 2026, while an archived version of the webcast will be available on the Investor Relations website for 90 days.

U.S. replay dial-in: 1-844-512-2921
International replay dial-in: 1-412-317-6671
Replay ID: 10212806

About Clearfield, Inc.
Clearfield, Inc. (NASDAQ: CLFD) designs, manufactures, and distributes fiber optic management, protection, and delivery solutions that enable high-performance connectivity across a wide range of markets, helping to close the digital divide. Clearfield’s labor lite, craft-friendly platform is leveraged by community broadband providers, MSOs, incumbent service providers, ISPs, data centers, wireless providers, IoT networks, the military, municipalities, and cooperatives to connect homes, businesses and critical infrastructure faster and more efficiently. Headquartered in Minneapolis, MN, Clearfield deploys more than a million fiber ports each year. For more information, visit www.SeeClearfield.com.

Cautionary Statement Regarding Forward-Looking Information

Forward-looking statements contained herein and in any related presentation or in the related Earnings Presentation are made pursuant to the safe harbor provisions of the Private Litigation Reform Act of 1995. Words such as “may,” “plan,” “expect,” “aim,” “believe,” “project,” “target,” “anticipate,” “intend,” “estimate,” “will,” “should,” “could,” “outlook,” or “continue” or comparable terminology are intended to identify forward-looking statements. Such forward looking statements include, for example, statements about the Company’s future revenue and operating performance, the development and marketing of new products, the impact of recent trade policy changes, including new and increased tariffs, retaliatory tariffs, trade disputes, and market and economic reactions to such changes, expected customer ordering patterns and future supply agreements with customers, expectations regarding the impact on our business of M&A activity among our customers, anticipated shipping on backlog and future lead times, future availability of components and materials from the Company’s supply chain, compliance with Build America Buy America (BABA) Act requirements, the impact of the Broadband Equity, Access, and Deployment (BEAD) Program, Rural Digital Opportunity Fund (RDOF) or other government programs on the demand for the Company’s products or timing of customer orders, the Company’s ability to match capacity to meet demand, expansion into new markets and trends in and growth of the FTTx markets, market segments or customer purchases, and other statements that are not historical facts. These statements are based upon the Company’s current expectations and judgments about future developments in the Company’s business. Certain important factors could have a material impact on the Company’s performance, including, without limitation: we depend on the availability of sufficient supply of certain materials and global disruptions in the supply chain for these materials could prevent us from meeting customer demand for our products; we rely on single-source suppliers, which could cause delays, increase costs or prevent us from completing customer orders; changes in trade policy in the U.S. and other countries may adversely affect our business and results of operations; inflationary price pressures and uncertain availability of components, raw materials, labor and logistics used by us and our suppliers could negatively impact our profitability; a significant percentage of our sales in the last three fiscal years have been made to a small number of customers, and the loss of these major customers could adversely affect us; further consolidation among our customers may result in the loss of some customers and may reduce sales during the pendency of business combinations and related integration activities; our business is dependent on interdependent management information systems; we may be subject to risks associated with acquisitions, and the risks could adversely affect future operating results; adverse global economic conditions and geopolitical issues could have a negative effect on our business, and results of operations and financial condition; product defects or the failure of our products to meet specifications could cause us to lose customers and sales or to incur unexpected expenses; we are dependent on key personnel; cyber-security incidents, including ransomware, data breaches or computer viruses, could disrupt our business operations, damage our reputation, result in increased expense, and potentially lead to legal proceedings; natural disasters, extreme weather conditions or other catastrophic events could negatively affect our business, financial condition, and operating results; to compete effectively, we must continually improve existing products and introduce new products that achieve market acceptance; our business is dependent upon capital spending by broadband service providers, and any delay, reduction or cancellation in capital spending by broadband service providers could adversely affect our business; if the telecommunications market does not continue to expand, our business may not grow as fast as we expect, which could adversely impact our business, financial condition and operating results; changes in U.S. government funding programs may cause our customers and prospective customers to delay, reduce, or accelerate purchases, leading to unpredictable and irregular purchase cycles; intense competition in our industry may result in price reductions, lower gross profits and loss of market share; our success depends upon adequate protection of our patent and intellectual property rights; we face risks associated with expanding our sales outside of the United States; our operating results may fluctuate significantly from quarter to quarter, which may make budgeting for expenses difficult and may negatively affect the market price of our common stock; our stock price has been volatile historically and may continue to be volatile – the price of our common stock may fluctuate significantly; anti-takeover provisions in our organizational documents, Minnesota law and other agreements could prevent or delay a change in control of our Company; and other factors set forth in Part I, Item IA. Risk Factors of Clearfield’s Annual Report on Form 10-K for the year ended September 30, 2025 as well as other filings with the Securities and Exchange Commission. The Company undertakes no obligation to update these statements to reflect actual events unless required by law.

Investor Relations Contact:
Greg McNiff
The Blueshirt Group
773-485-7191
clearfield@blueshirtgroup.com

CLEARFIELD, INC.
CONSOLIDATED STATEMENTS OF EARNINGS
(UNAUDITED)
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
		Three Months Ended								Year Ended
		September 30,				September 30,				September 30,				September 30,
			2026				2025				2026				2025
Net sales		$	39,343			$	41,060			$	151,939			$	150,134
Cost of sales			27,278				26,835				103,381				99,597
Gross profit			12,065				14,225				48,558				50,537
Operating expenses
Selling, general and administrative			13,114				13,271				50,929				48,419
(Loss) income from continuing operations			(1,049	)			954				(2,371	)			2,118
Net investment income			1,452				1,629				5,726				6,549
Income (loss) from continuing operations before income taxes			403				2,583				3,355				8,667
Income tax expense (benefit)			476				794				1,233				2,357
Income (loss) from continuing operations, net of tax			(73	)			1,789				2,122				6,310
Loss from discontinued operations, net of tax			–				(453	)			(337	)			(3,947	)
Loss from impairment of discontinued operations, net of tax			–				(10,413	)			–				(10,413	)
Net income (loss)		$	(73	)		$	(9,077	)		$	1,785			$	(8,050	)
Income (loss) per share
Basic
Continuing operations		$	0.00			$	0.13			$	0.16			$	0.45
Discontinued operations			–				(0.78	)			(0.02	)			(1.03	)
Basic income (loss) per share		$	0.00			$	(0.65	)		$	0.14			$	(0.58	)
Diluted
Continuing operations		$	0.00			$	0.13			$	0.16			$	0.45
Discontinued operations			–				(0.78	)			(0.02	)			(1.03	)
Diluted income (loss) per share		$	0.00			$	(0.65	)		$	0.14			$	(0.58	)
Weighted average shares outstanding:
Basic			13,572,702				13,816,449				13,676,450				13,989,489
Diluted			13,572,702				13,816,449				13,676,450				13,989,489

CLEARFIELD, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
		September 30, 2026				September 30, 2025
Assets
Current assets
Cash and cash equivalents		$	29,295			$	21,493
Short-term investments			79,048				84,484
Accounts receivables, net			20,435				17,991
Inventories, net			37,930				42,031
Prepaid and other current assets			11,017				11,152
Current assets held for sale			–				21,337
Total current assets			177,725				198,488
Property, plant and equipment, net			8,925				9,682
Long-term investments			49,087				59,822
Goodwill			4,709				4,709
Intangible assets, net			7,506				9,353
Right-of-use lease assets			9,283				8,420
Deferred tax asset			9,624				10,263
Other non-current assets			445				608
Non-current assets held for sale			–				4,828
Total assets		$	267,304			$	306,173
Liabilities and Shareholders’ Equity
Current liabilities
Current portion of lease liability		$	2,816			$	2,823
Accounts payable			6,924				7,028
Accrued compensation			4,823				6,598
Accrued expenses			1,241				2,197
Current liabilities held for sale			–				17,957
Total current liabilities			15,804				36,603
Other liabilities
Long-term portion of lease liability			6,783				5,934
Non-current liabilities held for sale			–				7,473
Total liabilities			22,587				50,010
Shareholders’ equity
Preferred stock, $0.01 par value; 500,000 shares; no shares
issued or outstanding			–				–
Common stock, authorized 50,000,000, $0.01 par value;
13,537,530 and 13,839,675 shares issued and outstanding
as of September 30, 2026 and September 30, 2025, respectively			135				138
Additional paid-in capital			136,588				147,382
Accumulated other comprehensive (loss) income			(703	)			1,731
Retained earnings			108,697				106,912
Total shareholders’ equity			244,717				256,163
Total Liabilities and Shareholders’ Equity		$	267,304			$	306,173

CLEARFIELD, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(IN THOUSANDS)
		Year Ended
		September 30,				September 30,
			2026				2025
Cash flows from operating activities (continuing)
Net income (loss)		$	1,785			$	(8,050	)
Loss from discontinued operations, net of tax			337				3,947
Loss from impairment of discontinued operations, net of tax			–				10,413
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization			6,288				6,121
(Gain) loss on sale of assets			–				(284	)
Amortization of premium and discount on investments, net			(311	)			(1,777	)
Deferred taxes			842				(4,244	)
Stock-based compensation			4,649				4,597
Changes in operating assets and liabilities:
Accounts receivable			(2,444	)			(3,548	)
Inventories, net			4,101				13,643
Other assets			211				173
Accounts payable and accrued expenses			(2,837	)			5,562
Net cash provided by operating activities (continuing)			12,621				26,553
Cash flows from investing activities (continuing)
Purchases of property, plant and equipment and intangible assets			(3,597	)			(4,743	)
Proceeds from sale of property and equipment			–				903
Purchases of investments			(85,640	)			(119,074	)
Proceeds from maturities of investments			101,158				115,866
Cash paid on disposal of business			(1,012	)			–
Net cash provided by (used in) investing activities (continuing)			10,909				(7,048	)
Cash flows from financing activities (continuing)
Proceeds from issuance of common stock under employee stock purchase plan			513				595
Repurchase of shares for payment of withholding taxes for vested restricted stock grants			(1,019	)			(494	)
Withholding related to exercise of stock options			(142	)			(689	)
Issuance of stock under equity compensation plans			–				–
Repurchase of common stock			(15,293	)			(16,653	)
Net cash used in financing activities (continuing)			(15,941	)			(17,241	)
Cash flows from discontinued operations
Net cash provided by operating activities			1,380				2,897
Net cash used in investing activities			–				(1,796	)
Net cash (used in) provided by financing activities			(1,196	)			3,000
Net cash provided by (used in) discontinued operations			184				4,101
Effect of exchange rates on cash and cash equivalents			(13	)			(97	)
Net increase (decrease) in cash and cash equivalents			7,760				6,268
Change in cash held for sale			42				1,077
Cash and cash equivalents, beginning of period			21,493				14,148
Cash and cash equivalents, end of period		$	29,295			$	21,493
Supplemental disclosures for cash flow information
Cash (refunded) paid for income taxes, net		$	(1,463	)		$	1,670
Right of use assets obtained through lease liabilities		$	3,553			$	–
Non-cash financing activities
Cashless exercise of stock options		$	2,666			$	2,533

WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 4, 2026, the Company and its wholly owned subsidiary, GPCR Therapeutics USA Inc. (“GPCR USA”), entered into an Intellectual Property, Asset and License Assignment Agreement (the “Agreement”) with GPCRT Inc. (“GPCRT”), a company organized under the laws of the Republic of Korea, under which GPCRT has agreed to acquire the Company’s GPC-100 (burixafor) program assets for an aggregate cash purchase price of KRW 6.5 billion (approximately US$4.8 million).

The assets to be sold consist of the Company’s rights under its License and Collaboration Agreement with GPCR Therapeutics, Inc. dated January 19, 2025, together with the related contracts, intellectual property, clinical and regulatory data, materials and equipment of the Company and GPCR USA used in the GPC-100 program. GPC-100 is being evaluated in combination with propranolol for stem cell mobilization in patients with multiple myeloma, and GPCR USA completed its Phase 2 clinical trial of GPC-100 in January 2026. GPCR USA will remain a wholly owned subsidiary of Exicure following the closing.

Of the purchase price, KRW 500 million has previously been paid by GPCRT and will be credited against the purchase price, KRW 2.0 billion is payable on or before November 16, 2026 and the remaining KRW 4.0 billion is payable at the closing, in each case subject to any other payment date agreed by the parties in writing. From and after the closing, GPCRT will assume the obligations under the License and Collaboration Agreement, including future milestone and royalty payments, and under the assigned program contracts, and GPCRT will bear the costs of the GPC-100 program incurred on or after September 1, 2026, as provided in the Agreement. Exicure and GPCR USA will retain all other liabilities, including GPC-100 program liabilities incurred before September 1, 2026.

The closing is subject to customary closing conditions, including required approvals and third-party consents, a waiver and release from GPCR Therapeutics, Inc. and any approval of the Company’s stockholders that may be required. There can be no assurance that the transaction will be completed on the anticipated timetable or at all.

The sale of the GPC-100 program assets is part of the Company’s ongoing evaluation of strategic alternatives intended to maximize stockholder value and is expected to strengthen the Company’s financial position.

Additional information regarding the Agreement is included in the Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”).

About Exicure, Inc.

Exicure, Inc. (Nasdaq: XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and the suspension of its clinical and development activities, the Company has been evaluating strategic alternatives to maximize stockholder value. In January 2025, the Company acquired GPCR Therapeutics USA Inc., a clinical-stage biotechnology company developing treatments for blood disorders, whose lead program, GPC-100, has been evaluated for improving stem cell mobilization in multiple myeloma and sickle cell disease and for supporting cell and gene therapy. For more information, visit www.exicuretx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the proposed sale of the GPC-100 program assets, the expected timing of the interim payment and the closing, the satisfaction of closing conditions, the assumption of liabilities and the reimbursement of costs by GPCRT, the expected effect of the transaction on the Company’s financial position, and the Company’s evaluation of strategic alternatives, are forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “will,” “may” and similar expressions are intended to identify forward-looking statements. These statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that the closing conditions are not satisfied or waived, that required consents, waivers or approvals are not obtained, that GPCRT does not make the payments when due, that the parties modify the terms or structure of the transaction, that the Company may have limited or no operating business following the transaction, fluctuations in the exchange rate between the Korean won and the U.S. dollar, the Company’s liquidity and ability to continue as a going concern, and the Company’s ability to maintain the listing of its common stock on Nasdaq, as well as the risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 25, 2026, as updated by the Company’s subsequent filings with the SEC. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update them except as required by law.

Contact

Exicure, Inc.
Email: pr@exicuretx.com

TIME recognizes Sunrun CEO as a “Titan” for her leadership accelerating the adoption of home battery storage and distributed power plants, bringing new flexible capacity to the grid

SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN), America’s largest provider of home battery storage, solar, and home-to-grid power plants, today announced that CEO Mary Powell has been named to the 2026 TIME100 Climate list. Powell was selected in TIME’s “Titan” category, honoring leaders inspiring greater ambition and action on climate. This marks the second time Powell has been recognized by TIME as one of the world’s most influential business leaders.

“Under Powell’s leadership, Sunrun is helping households participate in the energy transition,” TIME said, adding that Sunrun “has grown from a residential solar provider in the U.S. into a major operator of home batteries that can send power back to the grid when it is most needed.”

TIME highlighted Sunrun’s historic battery dispatches last month, when 120,000 customer home batteries delivered a record amount of power to California’s grid during a heat wave.

During those dispatch events, the batteries provided critical flexibility and capacity to the state’s power system during peak demand, helping reduce reliance on fossil-fuel power plants and put downward pressure on real-time energy prices for the benefit of all households.

“I am again so honored to be recognized by TIME alongside so many inspiring leaders advancing climate action,” said Sunrun CEO Mary Powell. “Americans are choosing greater independence and the ability to generate and store their own power. Together, our customers’ systems act as a power plant that can share energy with the grid when it’s needed most. They’re moving from passive energy consumers to active participants in our energy system. We have an extraordinary opportunity to strengthen grid reliability, accelerate the transition to cleaner energy, and give families a meaningful role in the climate solution.”

Since Powell became CEO five years ago, Sunrun has doubled its customer base, growing from approximately 600,000 to more than 1.2 million customers. Powell also led the company’s strategic shift to a storage-first business model, scaling its installed battery systems from 23,000 to more than 284,000, representing over 5 gigawatt hours of dispatchable capacity.

From 2022 through 2025, Sunrun customers’ solar energy systems generated approximately 28.2 billion kilowatt hours of solar energy, helping to enable the avoidance of approximately 15 million metric tons of carbon emissions from entering the atmosphere.

Today, Sunrun operates the nation’s largest distributed power plant, with more than 164,000 households enrolled in programs that dispatch their stored energy to the grid.

Powell’s leadership has earned numerous accolades. In addition to the 2024 and 2026 TIME100 Climate lists, her honors include the 2026 CNBC Changemakers list, the 2024 Forbes 50 Sustainability Leaders list, Utility Dive’s 2019 Utility Executive of the Year, Fast Company’s 100 Most Creative People and Fast 50 Leaders in America lists, and the prestigious Rachel Carson Award for environmental impact.

See the full list TIME100 Climate 2026: https://time.com/collection/time100-climate/2026/

About Sunrun

Sunrun Inc. (Nasdaq: RUN) is America’s largest provider of home battery storage, solar, and home-to-grid power plants. As the pioneer of home energy systems offered through a no-upfront-cost subscription model, Sunrun empowers customers nationwide with greater energy control, security, and independence. Sunrun supports the grid by providing on-demand dispatchable power that helps prevent blackouts and lowers energy costs. Learn more at www.sunrun.com.

Media Contact
Wyatt Semanek
Sr. Director, Corporate Communications
press@sunrun.com

Investor & Analyst Contact
Patrick Jobin
SVP, Deputy CFO & Investor Relations Officer
investors@sunrun.com

Company Announcement

COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

2,961 shares at DKK 1,362.5,
17,676 shares at DKK 1,615,
949 shares at DKK 1,948,
25,635 shares at DKK 2,070,
6,100 shares at DKK 2,103,
4,063 shares at DKK 2,129,
2,606 shares at DKK 2,148
34,552 shares at DKK 2,175,
11,884 shares at DKK 2,317,
8,535 shares at DKK 2,381,
2,798 shares at DKK 2,408,
953 shares at DKK 2,491,
2,014 shares at DKK 2,492,
4,309 shares at DKK 2,585,
2,525 shares at DKK 2,594,
764 shares at DKK 2,641,
27,772 shares at DKK 2,661,
399 shares at DKK 2,680,
1,563 shares at DKK 2,688,
2,402 shares at DKK 2,698,
3,290 shares at DKK 2,806, and
1,078 shares at DKK 3,172.

Proceeds to the Company are approximately DKK 369.7 million. The increase corresponds to approximately 0.2641% of the Company’s share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No. 1493 of November 18, 2025, it is hereby announced, that the total nominal value of Genmab A/S’ share capital after the capital increase is DKK 62,570,683 which is made up of 62,570,683 shares of a nominal value of DKK 1 each, corresponding to 62,570,683 votes.

About Genmab 
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn, X, Facebook and Instagram.

Contact: 
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; HexaBody^®; DuoHexaBody^®, HexElect^® and KYSO^®.

Company Announcement no. 46
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

• 101126_CA46_Warrant Exercise

Inhibition of CD8+ T cells shortens survival in Annamycin-treated mice, demonstrating the immune system is a functional contributor to Annamycin’s antitumor activity, not a bystander

Annamycin achieves substantially higher pancreatic tissue exposure than doxorubicin, offering a potential explanation for why topoisomerase II, a validated target in pancreatic cancer, has never been successfully drugged there

HOUSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced new preclinical data showing that its lead drug candidate, Annamycin (naxtarubicin), combined with PD-1 immune checkpoint blockade, extended survival in pancreatic cancer models beyond that achieved with either agent alone. The findings will be presented today by Waldemar Priebe, PhD, of The University of Texas MD Anderson Cancer Center, in an oral presentation at the 6th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care organized by Moffitt Cancer Center, being held November 8–11, 2026 in Tampa, Florida.

The presentation, titled “Targeting pancreatic cancer with Annamycin and turning immune cold tumor into hot tumor,” is scheduled for November 10th at 2:45 p.m. ET during the symposium’s gastrointestinal and urologic malignancies session.

In a syngeneic, immunocompetent KPC mouse model of advanced pancreatic ductal adenocarcinoma, treatment with liposomal Annamycin (L-ANN) in combination with PD-1 checkpoint blockade significantly increased survival compared with cohorts treated with either agent alone. The result has been reconfirmed in a second, independent experiment. Pancreatic cancer is among the tumor types least responsive to immune checkpoint inhibitors such as pembrolizumab and nivolumab, in large part because its tumor microenvironment is immunologically “cold,” with few infiltrating T cells. The Company believes these data support the evaluation of Annamycin in combination with approved PD-1 inhibitors in pancreatic cancer and, potentially, in other tumors where efficacy of checkpoint inhibitors is limited by an immunologically cold microenvironment.

The combination result builds on a series of findings from Dr. Priebe’s laboratory. Topoisomerase II alpha (TOP2A) is elevated in pancreatic cancer, and its expression correlates with shorter overall survival and higher rates of metastasis; yet approved topoisomerase II -targeting agents such as doxorubicin have not proven effective in the disease. Pharmacokinetic studies show that Annamycin achieves substantially higher and more sustained exposure in pancreatic tissue than doxorubicin at the same dose, offering a potential explanation. In treated tumors, Annamycin was measured at high concentrations, accompanied by evidence of DNA damage consistent with topoisomerase II targeting and by significantly increased infiltration of both CD8+ cytotoxic T cells and CD4+ helper T cells. Inhibiting CD8+ T cells in treated animals shortened survival, demonstrating that these cells are functional contributors to Annamycin’s antitumor activity rather than bystanders. These data extend results presented at the AACR Annual Meeting in April 2026 and at the AACR Conference on Pancreatic Cancer in September 2026, which demonstrated Annamycin’s activity across human orthotopic and syngeneic pancreatic cancer models, including liver metastasis models, and first identified the contribution of CD8+ T cells to its antitumor effect.

“In April we showed Annamycin reaches pancreatic tumors in animal models and shrinks them. In September we showed the immune system is part of why. These data close the loop: when you pair Annamycin with a checkpoint inhibitor the animals live longer than with either drug alone,” said Walter Klemp, Chairman, President and Chief Executive Officer of Moleculin. “This combination logic presents an exciting opportunity for potentially enabling immuno-oncology approaches in pancreatic cancer, and it comes with an additional benefit as Annamycin, in contrast to doxorubicin, has been shown to avoid cardiotoxicity in preclinical and clinical studies. While our immediate priority remains the MIRACLE trial in AML and its Q1 2027 data readout, this body of work continues to expand the strategic value of Annamycin well beyond AML.”

“Topoisomerase II is a validated but effectively undrugged target in pancreatic cancer, not because the target is wrong but because doxorubicin does not appear to reach the pancreas and consequently pancreatic cancer in sufficient concentration. We have successfully demonstrated in preclinical models that Annamycin does,” said Dr. Priebe. “What we did not anticipate is that once it is there, its action increases tumor infiltration of functional CD8+ and CD4+ T lymphocytes, and that is what makes the combination with checkpoint blockade work.”

The pancreatic cancer research described in this release is preclinical, which may not be predictive of clinical outcomes. The Company is currently planning to sponsor an investigator initiated clinical trial of Annamycin for the treatment of pancreatic cancer in 2027.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), has shown to be an efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

The Company is conducting the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design, multi-center, randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating Annamycin in combination with cytarabine (also referred to as “Ara-C”), together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway toward a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.

For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin, the potential for Annamycin to be used in combination with immune checkpoint inhibitors or in indications other than AML, the timing and results of the second interim analysis of the MB-108 trial, the potential for the MB-108 trial to support a New Drug Application submission, the Company’s plans to sponsor an investigator-initiated clinical trial of Annamycin in pancreatic cancer, and the Company’s ability to secure additional financing to conduct its clinical trials. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the completion of the clinical trials described in this press release assumes the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com

Latest patent expands intellectual property protection for advanced physiological signal acquisition and processing

THE WOODLANDS, TX, Nov. 10, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,793,841, titled “Medical Devices With Circuitry For Capturing And Processing Physiological Signals,” further strengthening the Company’s intellectual property portfolio supporting its proprietary catheter-based sensing technology.

The newly issued patent covers medical devices and methods for capturing and processing physiological signals through advanced sensing and processing circuitry. The technology enables signal acquisition and processing near the biological source, supporting high-resolution sensing, efficient data transmission and real-time physiological monitoring.

“This latest patent further strengthens the intellectual property foundation supporting our proprietary sensing technology and reinforces our commitment to advancing precision nerve-targeted interventions,” commented Brad Hauser, Chief Executive Officer of Autonomix. “Our ability to capture and process physiological signals directly at their source represents what we believe is a key differentiator of our platform. We believe this technology has the potential to provide physicians with greater insight into neural activity and support more precise, informed treatment decisions across a broad range of clinical applications.”

The patented architecture incorporates distributed processing modules, configurable sensing capabilities and efficient data transmission designed to support high-density physiological signal acquisition within catheter-based devices. These capabilities may have applications across cardiovascular interventions, electrophysiology, pain management and other procedures requiring precise physiological monitoring.

The new patent builds upon Autonomix’s existing U.S. and international intellectual property portfolio, further strengthening protection for its proprietary sensing technology as the Company advances its development programs and explores additional clinical applications.

About Autonomix Medical, Inc. 

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements 

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include, but are not limited to, the anticipated significance of the Company’s intellectual property portfolio, the potential capabilities and applications of the Company’s patented sensing technologies, the versatility and scalability of the Company’s platform technology, and the potential for future clinical applications across multiple organ systems.

Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 27, 2026, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact 

JTC Team, LLC 
Jenene Thomas
908.824.0775
autonomix@jtcir.com

SANTA CLARA, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — The independent members of the NVIDIA Board have retained former acting U.S. Attorney of the Southern District of New York Joon H. Kim and his firm Wachtell, Lipton, Rosen & Katz to conduct a thorough and independent investigation as was announced on Sunday.

AUBURN, Alabama, Nov. 10, 2026 (GLOBE NEWSWIRE) — On November 10, 2026, the Board of Directors of Auburn National Bancorporation, Inc. (the “Company”) (Nasdaq: AUBN) declared a fourth quarter $0.27 per share cash dividend, payable December 28, 2026 to shareholders of record as of December 10, 2026.

About Auburn National Bancorporation, Inc.

Auburn National Bancorporation, Inc. (the “Company”) is the parent company of AuburnBank (the “Bank”), with total assets of approximately $1.0 billion. The Bank is an Alabama state-chartered bank that is a member of the Federal Reserve System, which has operated continuously since 1907. Both the Company and the Bank are headquartered in Auburn, Alabama. The Bank conducts its business in East Alabama, including Lee County and surrounding areas. The Bank currently operates seven full-service branches in Auburn, Opelika, Valley, and Notasulga, Alabama. The Bank also operates a loan production office in Phenix City, Alabama. Additional information about the Company and the Bank may be found by visiting www.auburnbank.com.

For additional information, contact:
David A. Hedges
President and CEO
(334) 821-9200

Financing positions San Lorenzo to systematically scale exploration and grow its technical and operational capabilities at its flagship Salvadora Project in Chile

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, Nov. 10, 2026 (GLOBE NEWSWIRE) — San Lorenzo Gold Corp. (“San Lorenzo” or the “Company“) (TSXV: SLG) is pleased to announce the successful closing of its previously announced upsized private placement (the “Offering“) for aggregate gross proceeds of C$80,000,320, with participation from leading global institutional investors specializing in the natural resources sector. The Offering was led by SCP Resource Finance LP and National Bank Financial Inc., as lead agents (the “Lead Agents“), on behalf of a syndicate of agents including BMO Nesbitt Burns Inc. and Haywood Securities Inc. (together with the Lead Agents, the “Agents“), on a “best efforts” agency basis. Argonaut Securities Pty Limited acted as financial advisor to the Company in connection with the Offering.

Brandon Gaspar, Chief Executive Officer of San Lorenzo, commented: “Raising C$80 million at this stage of our exploration is a significant milestone for San Lorenzo, particularly given the calibre of investors supporting the Company. These are among the world’s leading resource investors, with established track records of backing successful gold exploration companies, including several that have ultimately been acquired by major gold producers.

This financing gives us the flexibility to pursue a substantially larger exploration program across Salvadora, following up on results and testing new targets as we continue to expand our technical and operational capabilities. We are grateful for the confidence of both our new and existing shareholders. Our priority is to scale systematically, allocating capital where the geology justifies it, with a clear focus on creating long-term shareholder value.”

Offering Details

Pursuant to the Offering, the Company issued an aggregate of 15,094,400 common shares of the Company (the “Offered Shares“) at a price of C$5.30 per Offered Share, for aggregate gross proceeds of C$80,000,320, consisting of:

• 9,433,900 Offered Shares (the “LIFE Shares“) issued pursuant to the “listed issuer financing exemption” under Part 5A of National Instrument 45-106 – Prospectus Exemptions (“NI 45-106”), as modified by Coordinated Blanket Order 45-935 (the “LIFE Exemption”), for gross proceeds of C$49,999,670 (the “LIFE Offering“); and
• 5,660,500 Offered Shares (the “Non-LIFE Shares“) issued pursuant to other available prospectus exemptions (the “Non-LIFE Offering“), for gross proceeds of C$30,000,650.

The Company intends to use the net proceeds raised from the Offering for exploration drilling and technical studies at its Salvadora project, operational capabilities and infrastructure, and general corporate and working capital purposes.

The LIFE Shares issued pursuant to the LIFE Exemption are freely tradeable and are not subject to a hold period under applicable Canadian securities laws. The Non-LIFE Shares issued pursuant to the Non-LIFE Offering are subject to applicable resale restrictions, including, where applicable, a hold period under applicable Canadian securities laws expiring on March 11, 2027.

In connection with the Offering, the Company paid aggregate cash commissions and advisory fees of C$4,771,519 (excluding applicable taxes), representing 6.0% of the gross proceeds of the Offering, other than gross proceeds from sales to purchasers on the president’s list, in respect of which a reduced commission of 3.0% was paid.

The Offering remains subject to final acceptance by the TSX Venture Exchange.

MI 61-101 Disclosure

Brandon Gaspar, Chief Executive Officer and a director of the Company, and Al Kroontje, Executive Chair and a director of the Company, each an insider of the Company, purchased an aggregate of 75,472 Offered Shares under the Offering for aggregate gross proceeds of C$400,000. The participation of insiders in the Offering constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101“). The Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the securities issued to, nor the consideration paid by, such insiders exceeds 25% of the Company’s market capitalization.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act“) or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

Additional Information

Prelia Canada LLP acted as legal counsel to San Lorenzo. Bennett Jones LLP acted as legal counsel to the Agents.

About San Lorenzo

San Lorenzo Gold Corp. is a Canadian mineral exploration company advancing its 100%-owned Salvadora Project in Chile’s Atacama Region, approximately 15 kilometres from Codelco’s El Salvador copper-gold mine. The Company is conducting a systematic exploration program across the Salvadora property, including drilling, geophysics and surface exploration. San Lorenzo is focused on advancing exploration at Salvadora and testing a pipeline of exploration targets across the property.

For further information, please contact:

San Lorenzo Gold Corp.
Brandon Gaspar, Chief Executive Officer
Email: info@slgold.com
Investor Relations: Acuity Advisory Corp.

Telephone: +1-604-837-5440

Cautionary Note Regarding Forward-Looking Information

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of San Lorenzo. All statements included herein other than statements of historical fact are forward-looking information. Forward-looking information in this news release includes, but is not limited to, statements regarding: the receipt of final acceptance of the Offering by the TSX Venture Exchange; the anticipated use of the net proceeds of the Offering; the Company’s planned exploration, programs at the Salvadora Project; the expansion of the Company’s technical and operational capabilities; and the Company’s future plans, objectives and growth strategy. Such forward-looking information is based on assumptions management believes to be reasonable, including that the TSX Venture Exchange will grant final acceptance of the Offering, that the net proceeds will be used as anticipated, and that the Company will be able to carry out its exploration programs as planned. Such forward-looking information involves various risks and uncertainties, including risks inherent in mineral exploration, changes in market conditions, the availability of financing and personnel, and regulatory and permitting risks in Chile. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. Any forward-looking information is made as of the date of this release and, other than as required by applicable securities laws, San Lorenzo does not assume any obligation to update or revise it to reflect new events or circumstances.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.